Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Amcenestrant|DRUG: Tamoxifen|DRUG: Amcenestrant-matching placebo|DRUG: Tamoxifen-matching placebo
Sponsor: Sanofi
Collaborators: Breast International Group|Alliance Foundation Trials, LLC.|European Organisation for Research and Treatment of Cancer - EORTC